Company Monitoring Page for Roche

latest headlines for company on cafepharma

Roche’s Polivy continues its regulatory dance, will head to FDA for a form of blood cancer
Endpoints
Tue, 08/16/22 - 11:17 am
Tags:
Roche, Polivy, diffuse large B-cell lymphoma, FDA
Roche, Genentech sign license deal with Kiniksa for vixarelimab
Pharmaceutical Business Review
Thu, 08/4/22 - 10:54 am
Tags:
Kiniksa Pharmaceuticals, Roche, Genentech, vixarelimab, monoclonal antibodies
Coherus wins FDA approval for second Lucentis biosimilar, its third drug
BioPharma Dive
Wed, 08/3/22 - 09:26 pm
Tags:
Coherus Biosciences, biosimilars, Lucentis, Roche, Cimerli
It’s official: Roche is a Car-T player
EP Vantage
Wed, 08/3/22 - 10:42 am
Tags:
Roche, CAR-T, oncology, Poseida Therapeutics
Racing Merck and Pfizer, Roche readies to file subcutaneous Tecentriq after posting phase 3 data
Fierce Pharma
Tue, 08/2/22 - 10:54 am
Tags:
Roche, Pfizer, Merck, Tecentriq, clinical trials, cancer, checkpoint inhibitors
Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy
Fierce Biotech
Fri, 07/29/22 - 10:20 am
Tags:
Sarepta Therapeutics, SRP-9001, Duchenne Muscular Dystrophy, Roche, accelerated approvals
Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate
Fierce Pharma
Mon, 07/25/22 - 10:00 pm
Tags:
Regeneron, Eylea, Roche, Vabysmo
Roche, Biogen temper Alzheimer’s expectations in Q2 calls. Will Lilly follow suit in August?
Fierce Biotech
Fri, 07/22/22 - 11:21 am
Tags:
Alzheimer's disease, Roche, Biogen, Eli Lilly, lecanemab, gantenerumab, Aduhelm
Roche Sees More Growth Opportunities for Phesgo, Tecentriq; Still Optimistic on Tiragolumab
Precision Oncology News
Fri, 07/22/22 - 10:14 am
Tags:
Roche, earnings, oncology, Phesgo, Tecentriq
Roche CEO Severin Schwan to step down after 14 years
Pharmaforum
Thu, 07/21/22 - 10:42 am
Tags:
Roche, Pharma CEOs, Severin Schwan, Thomas Schinecker
Genentech rides up to 2nd target in Bicycle immuno-oncology collab
Fierce Biotech
Tue, 07/12/22 - 10:52 am
Tags:
Genentech, Bicycle Therapeutics, Roche, immuno-oncology
Ionis hands off an antisense drug for kidney disease, giving all rights to Roche
Endpoints
Mon, 07/11/22 - 06:23 pm
Tags:
Ionis Pharmaceuticals, Roche, IONIS-FB-LRx, clinical trials, immunoglobin A nephropathy, kidney disease
AstraZeneca, GSK and more weathered Q2's economic headwinds, but Roche's stock took a hit: analysts
Fierce Pharma
Wed, 07/6/22 - 11:41 pm
Tags:
AstraZeneca, GSK, Roche
FDA to decide on Roche’s lymphoma drug Lunsumio before year-end
Pharmaforum
Wed, 07/6/22 - 10:49 am
Tags:
Roche, Lunsumio, follicular lymphoma, T-cell engager, FDA, priority review
Medtech research spending set to slow in 2022
EP Vantage
Tue, 07/5/22 - 10:57 am
Tags:
Medtech, R&D, Abbott Labs, Becton Dickinson, Boston Scientific, EssilorLuxottica, JNJ, Medtronic, Philips, Roche, Siemens Healthineers, Stryker
Roche, Pfizer top list of ESG leaders in patient groups' view, but many still think pharmas can do better
Endpoints
Thu, 06/30/22 - 10:17 pm
Tags:
ESG, Roche, Pfizer, patient advocacy groups
Fierce NextGen: Despite another key trial failure, Alzheimer's therapy developers find reason for optimism
Fierce Biotech
Wed, 06/29/22 - 10:59 am
Tags:
Alzheimer's disease, clinical trials, crenezumab, Roche, Genentech
Big pharma’s key third-quarter data
EP Vantage
Tue, 06/28/22 - 10:37 am
Tags:
GSK, Roche, Pfizer, JNJ, AstraZeneca, Novo Nordisk vaccines, clinical trials, pneumococcal disease, crovalimab, rheumatoid arthritis
Up-and-down test sales and a bigger Medtronic: medtech in 2028
EP Vantage
Mon, 06/20/22 - 10:35 am
Tags:
Medtech, devices, Medtronic, Siemens, Stryker, Roche
Wipeout: Roche's anti-amyloid attack on presymptomatic Alzheimer's ends in failure
Fierce Biotech
Thu, 06/16/22 - 10:40 am
Tags:
Roche, Genentech, Alzheimer's disease, crenezumab

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.